Prospects of biological and synthetic pharmacotherapies for glioblastoma

References

• Ostrom QT, Gittleman H, Truitt G, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro Oncol. 2018;20:iv1–iv86.
   PubMed Web of Science ®Google Scholar
• Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61:215–225; discussion 226–229.
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–820.
   PubMed Web of Science ®Google Scholar
• Brennan CW, Verhaak RGW, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155:462–477.
   PubMed Web of Science ®Google Scholar
• Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.
   PubMed Web of Science ®Google Scholar
• Reifenberger G, Wirsching H-G, Knobbe-Thomsen CB, et al. Advances in the molecular genetics of gliomas - implications for classification and therapy. Nat Rev Clin Oncol. 2017;14:434–452.
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061–1068.
   PubMed Web of Science ®Google Scholar
• Ceccarelli M, Barthel FP, Malta TM, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016;164:550–563.
   PubMed Web of Science ®Google Scholar
• Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807–1812.
   PubMed Web of Science ®Google Scholar
• Bai H, Harmanci AS, Erson-Omay EZ, et al. Integrated genomic characterization of IDH1-mutant glioma malignant progression. Nat Genet. 2016;48:59–66.
   PubMed Web of Science ®Google Scholar
• Nobusawa S, Watanabe T, Kleihues P, et al. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009;15:6002–6007.
   PubMed Web of Science ®Google Scholar
• Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739–744.
   PubMed Web of Science ®Google Scholar
• Nunez FJ, Mendez FM, Kadiyala P, et al. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response. Sci Transl Med. 2019;11:eaaq1427.
   PubMed Web of Science ®Google Scholar
• Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765–773.
   PubMed Web of Science ®Google Scholar
• Bjerke L, Mackay A, Nandhabalan M, et al. Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov. 2013;3:512–519.
   PubMed Web of Science ®Google Scholar
• Koschmann C, Calinescu AA, Nunez FJ, et al. ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma. Sci Transl Med. 2016;8:328ra328.
   Web of Science ®Google Scholar
• Kamran N, Chandran M, Lowenstein PR, et al. Immature myeloid cells in the tumor microenvironment: implications for immunotherapy. Clin Immunol. 2018;189:34–42.
   PubMed Web of Science ®Google Scholar
• Park J, Kim CG, Shim JK, et al. Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma. OncoImmunology. 2019;8:e1525243.
   PubMed Web of Science ®Google Scholar
• Hung AL, Maxwell R, Theodros D, et al. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. OncoImmunology. 2018;7(8):e1466769.
   PubMed Web of Science ®Google Scholar
• Kamran N, Kadiyala P, Saxena M, et al. Immunosuppressive myeloid cells’ blockade in the glioma microenvironment enhances the efficacy of immune-stimulatory gene therapy. Mol Ther. 2017;25:232–248.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–2520.
   PubMed Web of Science ®Google Scholar
• Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189–2199.
   PubMed Web of Science ®Google Scholar
• Australian Pancreatic Cancer Genome I, Consortium IBC, Consortium IM-S, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–421.
   PubMed Web of Science ®Google Scholar
• Samstein RM, Lee C-H, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51:202–206.
   PubMed Web of Science ®Google Scholar
• Young JS, Dayani F, Morshed RA, et al. Immunotherapy for high grade gliomas: a clinical update and practical considerations for neurosurgeons. World Neurosurg. 2019.
   Web of Science ®Google Scholar
• Lee KM, Chuang E, Griffin M, et al. Molecular basis of T cell inactivation by CTLA-4. Science. 1998;282:2263–2266.
   PubMed Web of Science ®Google Scholar
• Syn NL, Teng MWL, Mok TSK, et al. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol. 2017;18:e731–e741.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. PNAS. 2003;100:4712–4717.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Omuro A, Brandes AA, et al. OS10.3 randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: checkMate 143. Neuro-Oncol. 2017;19:iii21–iii21.
   Google Scholar
• Fecci PE, Ochiai H, Mitchell DA, et al. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ t cell compartment without affecting regulatory T-cell function. Clin Cancer Res. 2007;13:2158–2167.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhang C, Liu X, et al. Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. OncoImmunology. 2016;5:e1196310.
   PubMed Web of Science ®Google Scholar
• Berghoff AS, Kiesel B, Widhalm G, et al. Correlation of immune phenotype with IDH mutation in diffuse glioma. Neuro-Oncol. 2017;19:1460–1468.
   PubMed Web of Science ®Google Scholar
• Nduom EK, Wei J, Yaghi NK, et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro-Oncol. 2016;18:195–205.
   PubMed Web of Science ®Google Scholar
• Salmon H, Idoyaga J, Rahman A, et al. Activation of CD103 + dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity. 2016;44:924–938.
   PubMed Web of Science ®Google Scholar
• Fong B, Jin R, Wang X, et al. Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients. PLoS ONE. 2012;7:e32614.
   PubMed Web of Science ®Google Scholar
• Omuro A, Vlahovic G, Lim M, et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro-Oncol. 2018;20:674–686.
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Mochizuki AY, Orpilla JR, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019;25:477–486.
   PubMed Web of Science ®Google Scholar
• Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. PNAS. 2003;100:8372–8377.
   PubMed Web of Science ®Google Scholar
• Gan HK, Cvrljevic AN, Johns TG. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. Febs J. 2013;280:5350–5370.
   PubMed Web of Science ®Google Scholar
• Reist CJ, Batra SK, Pegram CN, et al. In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent. Nucl Med Biol. 1997;24:639–647.
   PubMed Web of Science ®Google Scholar
• Ohman L, Gedda L, Hesselager G, et al. A new antibody recognizing the vIII mutation of human epidermal growth factor receptor. Tumor Biol. 2002;23:61–69.
   PubMedGoogle Scholar
• Maire CL, Ligon KL. Molecular pathologic diagnosis of epidermal growth factor receptor. Neuro Oncol. 2014;16:viii1–viii6.
   PubMed Web of Science ®Google Scholar
• Wikstrand CJ, Stanley SD, Humphrey PA, et al. Investigation of a synthetic peptide as immunogen for a variant epidermal growth factor receptor associated with gliomas. J Neuroimmunol. 1993;46:165–173.
   PubMed Web of Science ®Google Scholar
• Paff M, Alexandru-Abrams D, Hsu FPK, et al. The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients. Hum Vaccin Immunother. 2014;10:3322–3331.
   PubMed Web of Science ®Google Scholar
• Liau LM, Black KL, Prins RM, et al. Treatment of intracranial gliomas with bone marrow—derived dendritic cells pulsed with tumor antigens. J Neurosurg. 1999;90:1115–1124.
   PubMed Web of Science ®Google Scholar
• Elsamadicy AA, Chongsathidkiet P, Desai R, et al. Prospect of rindopepimut in the treatment of glioblastoma. Expert Opin Biol Ther. 2017;17:507–513.
   PubMed Web of Science ®Google Scholar
• Molecular Targeting YW. Treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4. Clin Cancer Res. 2006;12:3792–3802.
   PubMed Web of Science ®Google Scholar
• Mishima K, Johns TG, Luwor RB, et al. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res. 2001;61:5349–5354.
   PubMed Web of Science ®Google Scholar
• Jungbluth AA, Stockert E, Huang HJS, et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. PNAS. 2003;100:639–644.
   PubMed Web of Science ®Google Scholar
• Scott AM, Lee FT, Tebbutt N, et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. PNAS. 2007;104:4071–4076.
   PubMed Web of Science ®Google Scholar
• Oflazoglu E, Stone IJ, Gordon K, et al. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Cancer Res. 2008;14:6171–6180.
   PubMed Web of Science ®Google Scholar
• Phillips AC, Boghaert ER, Vaidya KS, et al. ABT-414, an antibody-drug conjugate targeting a tumor-selective EGFR epitope. Mol Cancer Ther. 2016;15:661–669.
   PubMed Web of Science ®Google Scholar
• Reilly EB, Phillips AC, Buchanan FG, et al. Characterization of ABT-806, a humanized tumor-specific anti-EGFR monoclonal antibody. Mol Cancer Ther. 2015;14:1141–1151.
   PubMed Web of Science ®Google Scholar
• Sampson JH, Archer GE, Mitchell DA, et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther. 2009;8:2773–2779.
   PubMed Web of Science ®Google Scholar
• Chen D, Yang J. Development of novel antigen receptors for CAR T-cell therapy directed toward solid malignancies. Transl Res. 2017;187:11–21.
   PubMed Web of Science ®Google Scholar
• Maus MV, June CH. Making better chimeric antigen receptors for adoptive T-cell therapy. Clin Cancer Res. 2016;22:1875–1884.
   PubMed Web of Science ®Google Scholar
• Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3:388–398.
   PubMed Web of Science ®Google Scholar
• Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016;16:566–581.
   PubMed Web of Science ®Google Scholar
• Brown CE, Badie B, Barish ME, et al. Bioactivity and safety of IL13R 2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res. 2015;21:4062–4072.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Brawley V, Hegde M, et al. HER2-specific chimeric antigen receptor-modified virus-specific t cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol. 2017;3:1094–1101.
   PubMed Web of Science ®Google Scholar
• O’Rourke DM, Nasrallah MP, Desai A, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9:eaaa0984.
   PubMed Web of Science ®Google Scholar
• Bagley SJ, Desai AS, Linette GP, et al. CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges. Neuro Oncol. 2018;20:1429–1438.
   PubMed Web of Science ®Google Scholar
• Petersen CT, Krenciute G. Next generation CAR T cells for the immunotherapy of high-grade glioma. Front Oncol. 2019;9:69.
   PubMed Web of Science ®Google Scholar
• Brown C, Alizadeh D, Starr R, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016;375:2561–2569.
   PubMed Web of Science ®Google Scholar
• Hegde M, Mukherjee M, Grada Z, et al. Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape. J Clin Invest. 2016;126:3036–3052.
   PubMed Web of Science ®Google Scholar
• Krenciute G, Prinzing BL, Yi Z, et al. Transgenic expression of IL15 improves antiglioma activity of IL13Rα2-CAR T cells but results in antigen loss variants. Cancer Immunol Res. 2017;5:571–581.
   PubMed Web of Science ®Google Scholar
• Charles NA, Holland EC, Gilbertson R, et al. The brain tumor microenvironment. Glia. 2012;60:502–514.
   PubMed Web of Science ®Google Scholar
• Quail DF, Joyce JA. The microenvironmental landscape of brain tumors. Cancer Cell. 2017;31:326–341.
   PubMed Web of Science ®Google Scholar
• John LB, Devaud C, Duong CPM, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013;19:5636–5646.
   PubMed Web of Science ®Google Scholar
• Westphal M, Yla-Herttuala S, Martin J, et al. Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:823–833.
   PubMed Web of Science ®Google Scholar
• Chiocca EA, Smith KM, McKinney B, et al. A phase I trial of Ad.hIFN-beta gene therapy for glioma. Mol Ther. 2008;16:618–626.
   PubMed Web of Science ®Google Scholar
• Yoshida J, Mizuno M, Fujii M, et al. Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon beta gene using cationic liposomes. Hum Gene Ther. 2004;15:77–86.
   PubMed Web of Science ®Google Scholar
• Colombo F, Barzon L, Franchin E, et al. Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther. 2005;12:835–848.
   PubMed Web of Science ®Google Scholar
• Candolfi M, Yagiz K, Wibowo M, et al. Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models. Clin Cancer Res. 2014;20:1555–1565.
   PubMed Web of Science ®Google Scholar
• Candolfi M, Yagiz K, Foulad D, et al. Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin Cancer Res. 2009;15:4401–4414.
   PubMed Web of Science ®Google Scholar
• Curtin JF, Liu N, Candolfi M, et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med. 2009;6:e10.
   PubMed Web of Science ®Google Scholar
• Pfeifer A, Verma IM. Gene therapy: promises and problems. Annu Rev Genomics Hum Genet. 2001;2:177–211.
   PubMed Web of Science ®Google Scholar
• Varela-Guruceaga M, Tejada-Solis S, Garcia-Moure M, et al. Oncolytic viruses as therapeutic tools for pediatric brain tumors. Cancers (Basel). 2018;10:226.
   PubMed Web of Science ®Google Scholar
• Chiocca EA, Rabkin SD. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res. 2014;2:295–300.
   PubMed Web of Science ®Google Scholar
• Chiocca EA, Abbed KM, Tatter S, et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther. 2004;10:958–966.
   PubMed Web of Science ®Google Scholar
• Lang FF, Conrad C, Gomez-Manzano C, et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol. 2018;36:1419–1427.
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Landolfi J, Vogelbaum MA, et al. Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. Neuro Oncol. 2018;20:1383–1392.
   PubMed Web of Science ®Google Scholar
• McGranahan T, Therkelsen KE, Ahmad S, et al. current state of immunotherapy for treatment of glioblastoma. Curr Treat Options Oncol. 2019;20:24.
   PubMed Web of Science ®Google Scholar
• Desjardins A, Gromeier M, Herndon JE 2nd, et al. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med. 2018;379:150–161.
   PubMed Web of Science ®Google Scholar
• Geletneky K, Hajda J, Angelova AL, et al. Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I/IIa glioblastoma trial. Mol Ther. 2017;25:2620–2634.
   PubMed Web of Science ®Google Scholar
• Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst. 2010;102:932–941.
   PubMed Web of Science ®Google Scholar
• Xiao M, Yang H, Xu W, et al. Inhibition of alpha-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 2012;26:1326–1338.
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18:553–567.
   PubMed Web of Science ®Google Scholar
• Viswanath P, Ronen SM. Metabolic reprogramming of pyruvate dehydrogenase is essential for the proliferation of glioma cells expressing mutant IDH1. Mol Cell Oncol. 2016;3:e1077922.
   PubMed Web of Science ®Google Scholar
• Leu S, von Felten S, Frank S, et al. IDH mutation is associated with higher risk of malignant transformation in low-grade glioma. J Neurooncol. 2016;127:363–372.
   PubMed Web of Science ®Google Scholar
• Modrek AS, Golub D, Khan T, et al. Low-grade astrocytoma mutations in IDH1, P53, and ATRX cooperate to block differentiation of human neural stem cells via repression of SOX2. Cell Rep. 2017;21:1267–1280.
   PubMed Web of Science ®Google Scholar
• Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012;483:474–478.
   PubMed Web of Science ®Google Scholar
• Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013;340:626–630.
   PubMed Web of Science ®Google Scholar
• Kopinja J, Sevilla R, Levitan D, et al. A brain penetrant mutant idh1 inhibitor provides in vivo survival benefit. Sci Rep. 2017;7:13853.
   Web of Science ®Google Scholar
• Ma T, Zou F, Pusch S, et al. Inhibitors of mutant isocitrate dehydrogenases 1 and 2 (mIDH1/2): an update and perspective. J Med Chem. 2018;61:8981–9003.
   PubMed Web of Science ®Google Scholar
• Andronesi OC, Arrillaga-Romany IC, Ly KI, et al. Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. Nat Commun. 2018;9:1474.
   PubMed Web of Science ®Google Scholar
• Sulkowski PL, Corso CD, Robinson ND, et al. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci Transl Med. 2017;9:eaal2463.
   PubMed Web of Science ®Google Scholar
• Megias-Vericat JE, Ballesta-Lopez O, Barragan E, et al. IDH1-mutated relapsed or refractory AML: current challenges and future prospects. Blood Lymphat Cancer. 2019;9:19–32.
   PubMed Web of Science ®Google Scholar
• Mazor T, Chesnelong C, Pankov A, et al. Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1. Proc Natl Acad Sci U S A. 2017;114:10743–10748.
   PubMed Web of Science ®Google Scholar
• Li D, Fawaz MV, Morin EE, et al. Effect of synthetic high density lipoproteins modification with polyethylene glycol on pharmacokinetics and pharmacodynamics. Mol Pharm. 2018;15:83–96.
   PubMedGoogle Scholar
• Lomis N, Westfall S, Farahdel L, et al. Human serum albumin nanoparticles for use in cancer drug delivery: process optimization and in vitro characterization. Nanomaterials (Basel). 2016;6:116.
   PubMedGoogle Scholar
• Siegal T, Rubinstein R, Bokstein F, et al. In vivo assessment of the window of barrier opening after osmotic blood—brain barrier disruption in humans. J Neurosurg. 2000;92:599–605.
   PubMed Web of Science ®Google Scholar
• Kuai R, Li D, Chen YE, et al. Nature’s multifunctional nanoparticles. ACS Nano. 2016;10:3015–3041.
   PubMed Web of Science ®Google Scholar
• Kuai R, Ochyl LJ, Bahjat KS, et al. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat Mater. 2017;16:489–496.
   PubMed Web of Science ®Google Scholar
• Masserini M. Nanoparticles for brain drug delivery. ISRN Biochem. 2013;2013:1–18.
   Google Scholar
• Anchordoquy TJ, Barenholz Y, Boraschi D, et al. Barriers in cancer nanomedicine: addressing challenges, looking for solutions. ACS Nano. 2017;11:12–18.
   PubMed Web of Science ®Google Scholar
• Jain KK. Use of nanoparticles for drug delivery in glioblastoma multiforme. Expert Rev Neurother. 2007;7:363–372.
   PubMed Web of Science ®Google Scholar
• Parrish KE, Sarkaria JN, Elmquist WF. Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood-brain barrier. Clin Pharmacol Ther. 2015;97:336–346.
   PubMed Web of Science ®Google Scholar
• van Tellingen O, Yetkin-Arik B, de Gooijer MC, et al. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat. 2015;19:1–12.
   PubMed Web of Science ®Google Scholar
• Zhang F, Xu C-L, Liu C-M. Drug delivery strategies to enhance the permeability of the blood-brain barrier for treatment of glioma. Drug Des Devel Ther. 2015;9:2089–2100.
   PubMed Web of Science ®Google Scholar
• Agrahari V, Burnouf P-A, Burnouf T, et al. Nanoformulation properties, characterization, and behavior in complex biological matrices: challenges and opportunities for brain-targeted drug delivery applications and enhanced translational potential. Adv Drug Deliv Rev. 2019;148:146–180.
   Web of Science ®Google Scholar
• Brooks WH, Netsky MG, Normansell DE, et al. Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J Exp Med. 1972;136:1631–1647.
   PubMed Web of Science ®Google Scholar
• Grossman SA, Ye X, Lesser G, et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res. 2011;17:5473–5480.
   PubMed Web of Science ®Google Scholar
• Lombardi G, Rumiato E, Bertorelle R, et al. Genetic factors associated with severe hematological toxicity in glioblastoma patients during radiation plus temozolomide treatment: a prospective study. Am J Clin Oncol. 2015;38:514–519.
   PubMed Web of Science ®Google Scholar
• Shankar GM, Kirtane AR, Miller JJ, et al. Genotype-targeted local therapy of glioma. Proc Natl Acad Sci USA. 2018;115:E8388–E8394.
   PubMed Web of Science ®Google Scholar
• Yu D, Khan OF, Suvà ML, et al. Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression. Proc Natl Acad Sci USA. 2017;114:E6147–E6156.
   PubMed Web of Science ®Google Scholar
• Wang DD, Raygor KP, Cage TA, et al. Prospective comparison of long-term pain relief rates after first-time microvascular decompression and stereotactic radiosurgery for trigeminal neuralgia. J Neurosurg. 2018;128:68–77.
   PubMed Web of Science ®Google Scholar
• Cook RL, Householder KT, Chung EP, et al. A critical evaluation of drug delivery from ligand modified nanoparticles: confounding small molecule distribution and efficacy in the central nervous system. J Control Release. 2015;220:89–97.
   PubMed Web of Science ®Google Scholar
• Kadiyala P, Li D, Nuñez FM, et al. High-density lipoprotein-mimicking nanodiscs for chemo-immunotherapy against glioblastoma multiforme. ACS Nano. 2019;13:1365–1384.
   PubMed Web of Science ®Google Scholar
• Krause BR, Remaley AT. Reconstituted HDL for the acute treatment of acute coronary syndrome. Curr Opin Lipidol. 2013;24:480–486.
   PubMed Web of Science ®Google Scholar
• Sugahara KN, Teesalu T, Karmali PP, et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell. 2009;16:510–520.
   PubMed Web of Science ®Google Scholar
• Miao L, Lin CM, Huang L. Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors. J Control Release. 2015;219:192–204.
   PubMed Web of Science ®Google Scholar
• Carpentier A, Canney M, Vignot A, et al. Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Sci Transl Med. 2016;8:343re342–343re342.
   Web of Science ®Google Scholar
• Liu H-L, Hua M-Y, Chen P-Y, et al. Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. Radiology. 2010;255:415–425.
   PubMed Web of Science ®Google Scholar
• Carpentier A, Laigle-Donadey F, Zohar S, et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma1. Neuro Oncol. 2006;8:60–66.
   PubMed Web of Science ®Google Scholar
• Elliott PJ, Hayward NJ, Huff MR, et al. Unlocking the blood–brain barrier: a role for RMP-7 in brain tumor therapy. Exp Neurol. 1996;141:214–224.
   PubMed Web of Science ®Google Scholar
• Lin F, de Gooijer MC, Hanekamp D, et al. Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux. CNS Oncol. 2013;2:271–288.
   PubMedGoogle Scholar
• Ché C, Yang G, Thiot C, et al. new angiopep-modified doxorubicin (ANG1007) and Etoposide (ANG1009) chemotherapeutics with increased brain penetration. J Med Chem. 2010;53:2814–2824.
   PubMed Web of Science ®Google Scholar
• Tseng WL, Hsu HH, Chen Y, et al. Tumor recurrence in a glioblastoma patient after discontinuation of prolonged temozolomide treatment. Asian J Neurosurg. 2017;12:727–730.
   PubMedGoogle Scholar
• Qian Y, Maruyama S, Kim H, et al. Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma. Neuro Oncol. 2017;19:1651–1660.
   PubMed Web of Science ®Google Scholar
• Miyai M, Tomita H, Soeda A, et al. Current trends in mouse models of glioblastoma. J Neurooncol. 2017;135:423–432.
   PubMed Web of Science ®Google Scholar
• Trinh A, Polyak, K. Tumor neoantigens: when too much of a good thing is bad. Cancer Cell. 2019;36:466–467.
   PubMed Web of Science ®Google Scholar
• Yuan J, Levitin HM, Frattini V, et al. Single-cell transcriptome analysis of lineage diversity in high-grade glioma. Genome Med. 2018;10:57.
   PubMed Web of Science ®Google Scholar
• Olin MR, Ampudia-Mesias E, Pennell CA, et al. Treatment combining CD200 immune checkpoint inhibitor and tumor-lysate vaccination after surgery for pet dogs with high-grade glioma. Cancers (Basel). 2019;11:137.
   PubMed Web of Science ®Google Scholar